Prion Peptide Hemin Binders for Stroke Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Hemin toxicity following hemorrhagic stroke causes brain damage due to elevated hemin levels, which existing methods fail to effectively mitigate.
Innovation Solution
Utilizing specific amino acid sequences from the N-terminal domain of prion protein (PrPC) to bind hemin, forming chemical bonds and reducing toxic effects, administered as a composition to treat conditions with cellularly toxic hemin levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing methods are used to treat hemorrhagic stroke, then standard care is provided, but hemin toxicity causes brain damage and tissue injury
Solution Approach 1:
The patent introduces an intermediary substance (hemin binder such as HMB-2) that mediates between the toxic hemin and the neural tissue. The binder selectively binds hemin with high affinity, forming a complex that prevents hemin from interacting with and damaging cells, while allowing the body to naturally clear the complex. This resolves the contradiction by adding a protective intermediary that eliminates hemin's harmful effects without interfering with essential physiological processes.
Solution Approach 2:
The patent converts the harmful presence of hemin into a beneficial therapeutic opportunity. By administering a hemin binder specifically after hemorrhagic stroke, the treatment transforms the toxic situation into a controlled binding event where hemin is sequestered and neutralized. The same hemin that causes damage is now the target of a therapeutic intervention, converting the harmful factor into the basis for effective treatment.
2Productivity
If hemin levels are allowed to remain elevated, then the body's natural hemoglobin breakdown is maintained, but tissue injury and neurodegeneration occur
Solution Approach 1:
The patent extracts the harmful element (hemin) from the physiological process of hemoglobin breakdown by introducing an exogenous binder that selectively removes hemin from the system. The binder does not interfere with the natural breakdown of hemoglobin but specifically extracts the toxic hemin product, allowing the body to continue its natural hemoglobin metabolism while preventing hemin accumulation and associated tissue damage.
3Object-affected harmful factors
If hemin is cleared rapidly, then tissue injury is prevented, but the natural physiological process of hemoglobin breakdown is disrupted
Solution Approach 1:
The hemin binder acts as a selective intermediary that distinguishes between free toxic hemin and hemin bound in normal physiological complexes. The binder has high affinity for free hemin but does not disrupt stable hemoglobin-heme complexes, thereby preventing tissue injury while preserving essential physiological functions. This selective mediation maintains physiological stability while eliminating harmful effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amino acid sequences effectively bind hemin, preventing tissue injury and neurodegeneration by reducing hemin toxicity, particularly in stroke-related conditions, with increased binding capacity at lower pH levels.
Implementation Method 1
the isolated amino acid sequence is effective for forming one or more chemical bonds with hemin
Implementation Method 2
amino acid sequences found in prion protein to bind hemin
Data Source
AI summary
Methods of using portions of the N-terminal domain of prion protein for binding hemin are disclosed. In a particular embodiment, a method comprises administering at least one isolated amino acid sequence comprising a peptide from the octarepeat region of PrPC to a solution containing hemin, wherein the isolated amino acid sequence is effective for forming one or more chemical bonds with hemin.